Drug Profile
SM 12502
Alternative Names: SM-12502Latest Information Update: 30 Aug 2007
Price :
$50
*
At a glance
- Originator Sumitomo Pharmaceuticals
- Class Antiplatelets
- Mechanism of Action Platelet activating factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Disseminated intravascular coagulation; Shock